{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:07:22Z","timestamp":1777093642533,"version":"3.51.4"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800150"],"award-info":[{"award-number":["81800150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation for Young Scientists of Chinese PLA General Hospital","award":["QNF19043"],"award-info":[{"award-number":["QNF19043"]}]},{"name":"Innovative Foundation of Chinese PLA General Hospital","award":["CX19016"],"award-info":[{"award-number":["CX19016"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Post-remission strategies for patients with acute lymphoblastic leukemia (ALL) are limited to the multiagent chemotherapy and allogeneic stem cell transplant (allo-SCT), and cellular therapies are seldom involved. Although chemotherapy combined with mismatched granulocyte colony-stimulating factor mobilized peripheral blood mononuclear cell infusion (microtransplant, MST) has been studied in patients with acute myeloid leukemia, its efficacy in ALL is still undetermined. We enrolled 48 patients receiving hyper-CVAD-based MST between July 1, 2009, and January 31, 2018. No acute or chronic graft-versus-host disease occurred in patients receiving MST. Four-year overall survival (OS) and leukemia-free survival (LFS) were 62% and 35%, respectively, and the 4-year relapse rate was 65%. No patient experienced non\u2013relapse mortality. Subgroup analysis showed that OS rates were comparable between groups with different age, risk stratification, minimal residual disease status prior to MST and immunophenotype. Adult patients tended to achieve better 4-year LFS (62% vs. 26%, P = .058) and lower hematologic relapse rate (38% vs. 74%, P = .058) compared with adolescent and young adult patients. Donor chimerism\/microchimerism was detectable ranging from 0.002% to 42.78% in 78% (42\/54) available samples within 14 days after each infusion and at 3 months or one year after the last cell infusion. Multivariate analyses demonstrated that white blood cells &amp;lt;30 \u00d7 109\/L at diagnosis and sufficient hyper-CVAD cycles were prognostic factors for better 4-year OS and LFS, while the B-cell phenotype and higher number of infused CD34+ cells in the first cycle were predictors for favorable 4-year LFS. The hyper-CVAD-based MST was a feasible strategy for treating ALL patients with mild toxicity.<\/jats:p>","DOI":"10.1093\/stcltm\/szac066","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T22:48:02Z","timestamp":1664664482000},"page":"1113-1122","source":"Crossref","is-referenced-by-count":4,"title":["Hyper-CVAD-Based Stem Cell Microtransplant as Post-Remission Therapy in Acute Lymphoblastic Leukemia"],"prefix":"10.1093","volume":"11","author":[{"given":"Bo","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiyun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-8458","authenticated-orcid":false,"given":"Kaixun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqing","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tieqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuecong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujie","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anli","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Ning","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxing","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayue","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Capital Medical University , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huisheng","family":"Ai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlin","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-8873","authenticated-orcid":false,"given":"Mei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Fifth Medical Center, Chinese PLA General Hospital , Beijing , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"issue":"11","key":"2022111808194997500_CIT0001","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia."},{"issue":"5","key":"2022111808194997500_CIT0002","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2022111808194997500_CIT0003","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"2022111808194997500_CIT0004","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s00262-021-02941-4","article-title":"CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease","volume":"70","author":"Lu","year":"2021","journal-title":"Cancer Immunol Immunother."},{"issue":"14","key":"2022111808194997500_CIT0005","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"},{"issue":"17","key":"2022111808194997500_CIT0006","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Foa","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"2022111808194997500_CIT0007","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1001\/jamaoncol.2017.2656","article-title":"HLA-mismatched microtransplant in older patients newly diagnosed with acute myeloid leukemia: results from the microtransplantation interest group","volume":"4","author":"Guo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"33","key":"2022111808194997500_CIT0008","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1200\/JCO.2012.42.0281","article-title":"HLA-mismatched stem-cell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up","volume":"30","author":"Guo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2022111808194997500_CIT0009","doi-asserted-by":"crossref","first-page":"524","DOI":"10.5966\/sctm.2015-0196","article-title":"A study of human leukocyte antigen mismatched cellular therapy (stem cell microtransplantation) in high-risk myelodysplastic syndrome or transformed acute myelogenous leukemia","volume":"5","author":"Hu","year":"2016","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"2022111808194997500_CIT0010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/10428194.2014.914196","article-title":"Programmed haploidentical hematopoietic stem cell infusion combined with systemic chemotherapy improves the outcomes of patients with refractory or relapsed lymphoma","volume":"56","author":"Zhao","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"2022111808194997500_CIT0011","first-page":"3852","article-title":"Comparison of microtransplantation, chemotherapy and allogeneic transplantation in post-remission therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"10","author":"Cai","year":"2020","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2022111808194997500_CIT0012","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood-2010-06-288506","article-title":"Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients","volume":"117","author":"Guo","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2022111808194997500_CIT0013","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2022111808194997500_CIT0014","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute lymphoblastic leukemia, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"issue":"12","key":"2022111808194997500_CIT0015","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"24","key":"2022111808194997500_CIT0016","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022111808194997500_CIT0017","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"2022111808194997500_CIT0018","doi-asserted-by":"crossref","first-page":"2040620720903531","DOI":"10.1177\/2040620720903531","article-title":"Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population","volume":"11","author":"Carobolante","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"2022111808194997500_CIT0019","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fonc.2014.00054","article-title":"Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"4","author":"Bernt","year":"2014","journal-title":"Front Oncol"},{"issue":"12","key":"2022111808194997500_CIT0020","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"8","key":"2022111808194997500_CIT0021","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2022111808194997500_CIT0022","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ajh.25781","article-title":"Microtransplantation in older patients with AML: a pilot study of safety, efficacy and immunologic effects","volume":"95","author":"Sung","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"2022111808194997500_CIT0023","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbmt.2017.12.802","article-title":"Ultra-sensitive droplet digital PCR for the assessment of microchimerism in cellular therapies","volume":"24","author":"Kliman","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"2022111808194997500_CIT0024","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1182\/bloodadvances.2020002805","article-title":"Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response","volume":"4","author":"Chaekal","year":"2020","journal-title":"Blood Adv"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/11\/1113\/47107945\/szac066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/11\/11\/1113\/47107945\/szac066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T08:20:19Z","timestamp":1668759619000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/11\/11\/1113\/6743288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,10,1]]},"published-print":{"date-parts":[[2022,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szac066","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,10,1]]}}}